Thank you for your interest in research for age-related macular degeneration (AMD).
Having trouble reading this form? Call us to learn more about research in your area:
Gyroscope Therapeutics is a clinical-stage gene therapy company focused on diseases of the eye. In February 2022, Gyroscope was acquired by Novartis, a leading global medicines company. We are working with some of the world’s leading gene therapy and retina experts to evaluate whether our investigational gene therapy, GT005, can slow the progression of advanced dry AMD that can lead to blindness. We are also conducting broad observational studies to learn more about the impact of genetics on advanced dry AMD or geographic atrophy (GA). You can learn more about specific Gyroscope studies here.
If you or a loved one have been diagnosed with AMD and would like to learn more about participating in Gyroscope’s research program, please complete our brief screening questionnaire below.
The first section asks a few questions to obtain permission to collect, process and store your personal data in association with a Gyroscope Therapeutics clinical trial and for the purpose of evaluating your potential eligibility. If determined that you might be eligible, a representative from Gyroscope will reach out to you to provide you with a letter to bring to your current eye care provider, who will further evaluate your eligibility. If your eye care provider thinks you appear to be a candidate, your eye care provider may refer you to a Gyroscope Therapeutics clinical trial investigator so they can further assess the information collected to discuss your potential participation. We will also forward your name and primary eyecare provider to the Gyroscope Therapeutics clinical trial investigator. After providing the letter to you and forwarding your information to the investigator, Gyroscope will delete your personal information.
For the purposes of this questionnaire, a clinical trial site is defined as a selected clinic participating in Gyroscope sponsored studies for GA. GA is a form of advanced dry AMD associated with loss of retina/tissue in the back of eyes that may lead to vision loss.